Antonella Zagaria

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2459423/publications.pdf

Version: 2024-02-01

331670 434195 1,301 80 21 31 citations h-index g-index papers 80 80 80 1767 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	<i>RUNX1</i> gene alterations characterized by allelic preference in adult acute myeloid leukemia. Leukemia and Lymphoma, 2023, 64, 717-721.	1.3	4
2	FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches. Blood Reviews, 2022, 54, 100928.	5.7	4
3	Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?. International Journal of Molecular Sciences, 2022, 23, 3177.	4.1	5
4	Single-Cell Sequencing: Ariadne's Thread in the Maze of Acute Myeloid Leukemia. Diagnostics, 2022, 12, 996.	2.6	2
5	Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link?. Frontiers in Oncology, 2022, 12, 873896.	2.8	12
6	Erythrocytosis with JAK2 GGCC_46/1 haplotype and without JAK2 V617F mutation is associated with CALR rs1049481_G allele. Leukemia, 2021, 35, 619-622.	7.2	5
7	Nanopore sequencing sheds a light on the <i>FLT3</i> gene mutations complexity in acute promyelocytic leukemia. Leukemia and Lymphoma, 2021, 62, 1219-1225.	1.3	5
8	Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers. International Journal of Molecular Sciences, 2021, 22, 7156.	4.1	21
9	Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?. Cancers, 2021, 13, 4121.	3.7	2
10	Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia. Scientific Reports, 2021, 11, 17668.	3.3	6
11	IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis. Experimental Hematology and Oncology, 2021, 10, 58.	5.0	3
12	Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick. Biomarker Research, 2021, 9, 89.	6.8	5
13	TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings. International Journal of Molecular Sciences, 2020, 21, 3432.	4.1	25
14	Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies. International Journal of Molecular Sciences, 2020, 21, 3141.	4.1	35
15	HMGA Proteins in Hematological Malignancies. Cancers, 2020, 12, 1456.	3.7	8
16	Nanopore Sequencing in Blood Diseases: A Wide Range of Opportunities. Frontiers in Genetics, 2020, 11, 76.	2.3	29
17	Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine?. Cancers, 2020, 12, 185.	3.7	22
18	<p>Skin lesions in chronic myeloid leukemia patients during dasatinib treatment</p> . Cancer Management and Research, 2019, Volume 11, 7991-7996.	1.9	7

#	Article	IF	Citations
19	RARG Gene Dysregulation in Acute Myeloid Leukemia. Frontiers in Molecular Biosciences, 2019, 6, 114.	3.5	18
20	A complex and cryptic intrachromosomal rearrangement generating the FIP1L1_PDGFRA in adult acute myeloid leukemia. Cancer Genetics, 2019, 239, 8-12.	0.4	0
21	Next-Generation Sequencing in Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 2019, 20, 2929.	4.1	60
22	The Pleiotropic Role of Retinoic Acid/Retinoic Acid Receptors Signaling: From Vitamin A Metabolism to Gene Rearrangements in Acute Promyelocytic Leukemia. International Journal of Molecular Sciences, 2019, 20, 2921.	4.1	16
23	Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia. Genes, 2019, 10, 1026.	2.4	26
24	Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia. Journal of Molecular Diagnostics, 2018, 20, 474-482.	2.8	41
25	RARA and RARG gene downregulation associated with EZH2 mutation in acute promyelocytic-like morphology leukemia. Human Pathology, 2018, 80, 82-86.	2.0	19
26	A novel $t(3;9)(q21.2; p24.3)$ associated with SMARCA2 and ZNF148 genes rearrangement in myelodysplastic syndrome. Leukemia and Lymphoma, 2018, 59, 996-999.	1.3	4
27	Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies. Diagnostic Pathology, 2018, 13, 98.	2.0	7
28	Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring―of residual disease in chronic myeloid leukemia patients. Oncotarget, 2018, 9, 10978-10986.	1.8	29
29	The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?. International Journal of Molecular Sciences, 2018, 19, 1152.	4.1	16
30	Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia. Scientific Reports, 2018, 8, 11798.	3.3	34
31	Droplet Digital PCR Is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukemia. Journal of Molecular Diagnostics, 2017, 19, 437-444.	2.8	34
32	CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?. Expert Review of Hematology, 2017, 10, 853-862.	2.2	21
33	Mutational analysis in BCR - ABL1 positive leukemia by deep sequencing based on nanopore MinION technology. Experimental and Molecular Pathology, 2017, 103, 33-37.	2.1	36
34	Monosomal karyotype in myeloid neoplasias: a literature review. OncoTargets and Therapy, 2017, Volume 10, 2163-2171.	2.0	13
35	<i>SETBP1</i> dysregulation in congenital disorders and myeloid neoplasms. Oncotarget, 2017, 8, 51920-51935.	1.8	26
36	Droplet digital PCR analysis of <i>NOTCH1</i> gene mutations in chronic lymphocytic leukemia. Oncotarget, 2016, 7, 86469-86479.	1.8	23

#	Article	IF	Citations
37	Droplet digital PCR assay for quantifying of CALR mutant allelic burden in myeloproliferative neoplasms. Annals of Hematology, 2016, 95, 1559-1560.	1.8	16
38	TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing. Diagnostic Pathology, 2016, 11, 96.	2.0	51
39	MYEOV gene overexpression in primary plasma cell leukemia with t(11;14)(q13;q32). Oncology Letters, 2016, 12, 1460-1464.	1.8	7
40	Absolute quantification of the pretreatment <i>PML-RARA</i> transcript defines the relapse risk in acute promyelocytic leukemia. Oncotarget, 2015, 6, 13269-13277.	1.8	35
41	Overexpression of the LSAMP and TUSC7 genes in acute myeloid leukemia following microdeletion/duplication of chromosome 3. Cancer Genetics, 2015, 208, 517-522.	0.4	8
42	BCR–ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 357-363.	2.8	24
43	Centromeric fragment of chromosome 7 in atypical chronic myeloid leukemia with the SET binding protein 1 gene mutation. Leukemia and Lymphoma, 2015, 56, 826-828.	1.3	1
44	Myelodysplastic syndrome with 5q deletion following IgM monoclonal gammopathy, showing gene mutation MYD88 L265P. Blood Cells, Molecules, and Diseases, 2015, 54, 51-52.	1.4	5
45	Droplet Digital PCR Analysis for Diagnosis and Minimal Residual Disease Monitoring in Adult Ph+ Acute Lymphoblastic Leukemia. Blood, 2015, 126, 4989-4989.	1.4	1
46	5â€RUNX1-3'USP42 chimeric gene in acute myeloid leukemia can occur through an insertion mechanism rather than translocation and may be mediated by genomic segmental duplications. Molecular Cytogenetics, 2014, 7, 66.	0.9	11
47	BCL6 corepressor gene dysregulation due to chromosomal translocation in acute myeloid leukemia: a new mechanism based on long non-coding RNA dislocation?. Leukemia and Lymphoma, 2014, 55, 2199-2201.	1.3	2
48	ADAMTS2 gene dysregulation in T/myeloid mixed phenotype acute leukemia. BMC Cancer, 2014, 14, 963.	2.6	6
49	lgG-lymphoplasmacytic lymphoma following polycythemia vera: JAK2 V617F and MYD88 L265P mutations separated in the same house. Annals of Hematology, 2014, 93, 1605-1607.	1.8	8
50	Acute myeloid leukemia with $t(16;16)$ (p13;q22) showing a new CBFB-MYH11 fusion transcript associated with an atypical leukemic blasts morphology. Human Pathology, 2014, 45, 643-647.	2.0	10
51	Gene expression profiling of chronic myeloid leukemia with variant t(9;22) reveals a different signature from cases with classic translocation. Molecular Cancer, 2013, 12, 36.	19.2	14
52	A novel t(4;16)(q25;q23.1) associated with EGF and ELOVL6 deregulation in acute myeloid leukemia. Gene, 2013, 529, 144-147.	2.2	8
53	SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia. Journal of Hematology and Oncology, 2012, 5, 48.	17.0	27
54	A new recurrent chromosomal translocation $t(3;11)(q13;q14)$ in myelodysplastic syndromes associated with overexpression of the ILDR1 gene. Leukemia Research, 2012, 36, 852-856.	0.8	6

#	Article	IF	CITATIONS
55	Decreased TET2 gene expression during chronic myeloid leukemia progression. Leukemia Research, 2011, 35, e220-e222.	0.8	30
56	Genomic segmental duplications on the basis of the $t(9;22)$ rearrangement in chronic myeloid leukemia. Oncogene, 2010, 29, 2509-2516.	5.9	35
57	Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements. Molecular Cancer, 2010, 9, 120.	19.2	37
58	<i>MIRN199B</i> downregulation in chronic myeloid leukaemia is associated with deletions on der(9). British Journal of Haematology, 2009, 144, 271-273.	2.5	7
59	Downregulated expression of genes mapping on chromosome 9 in chronic myeloid leukemia cases bearing genomic deletions on der(9). Leukemia, 2009, 23, 813-816.	7.2	3
60	The double deceit generated by an insertion mechanism in chronic myeloid leukemia with t(9;9;22). Annals of Hematology, 2008, 87, 923-926.	1.8	1
61	Extramedullary molecular evidence of the 5′KIAA1509/3′PDGFRB fusion gene in chronic eosinophilic leukemia. Leukemia Research, 2008, 32, 347-351.	0.8	5
62	Genomic and molecular switching in relapsed acute promyelocytic leukemia. Leukemia, 2008, 22, 1469-1472.	7.2	1
63	"Home-brew―FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 2007, 174, 121-126.	1.0	23
64	Molecular cytogenetic findings supporting the evidence of a biclonal origin in acute myeloid leukemia. Annals of Hematology, 2006, 85, 129-131.	1.8	0
65	Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia. Cancer Genetics and Cytogenetics, 2006, 167, 97-102.	1.0	21
66	Submicroscopic deletions in an acute myeloid leukemia case with a four-way t(8;11;16;21). Leukemia Research, 2005, 29, 855-858.	0.8	12
67	Molecular cytogenetic study of instability at $1q21\hat{a}^4q32$ in adult acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2005, 156, 54-58.	1.0	4
68	Pericentric chromosome 8 inversion associated with the 5?RUNX1/3?CBFA2T1 gene in acute myeloid leukemia cases. Annals of Hematology, 2005, 84, 245-249.	1.8	7
69	A chronic myelocytic leukemia case bearing deletions on the three chromosomes involved in a variant t(9;22;11). Cancer Genetics and Cytogenetics, 2004, 148, 137-140.	1.0	7
70	A fluorescence in situ hybridization study of complex t(9;22) in two chronic myelocytic leukemia cases with a masked Philadelphia chromosome. Cancer Genetics and Cytogenetics, 2004, 150, 81-85.	1.0	25
71	A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1. Annals of Hematology, 2004, 83, 78-83.	1.8	26
72	Insertions generating the 5?RUNX1/3?CBFA2T1 gene in acute myeloid leukemia cases show variable breakpoints. Genes Chromosomes and Cancer, 2004, 41, 86-91.	2.8	19

#	Article	IF	CITATION
73	Derivative Chromosome 9 Deletions in Chronic Myeloid Leukemia are Associated with Loss of Tumor Suppressor Genes. Leukemia and Lymphoma, 2004, 45, 689-694.	1.3	17
74	Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases. Genes Chromosomes and Cancer, 2003, 36, 353-360.	2.8	17
75	Deletions on der(9) chromosome in adult Ph-positive acute lymphoblastic leukemia occur with a frequency similar to that observed in chronic myeloid leukemia. Leukemia, 2003, 17, 528-531.	7.2	8
76	A novel translocation $t(14;15)(q32;q24)$ bearing deletion on der(14) in Philadelphia-positive chronic myeloid leukemia. Haematologica, 2003, 88, 1076-7.	3.5	1
77	A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: Possible involvement in the genesis of the Philadelphia chromosome translocation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 9882-9887.	7.1	71
78	Molecular cytogenetic characterization of a complex rearrangement involving chromosomes 9 and 22 in a case of Ph-negative chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 2002, 136, 141-145.	1.0	12
79	Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chromosomes and Cancer, 2002, 35, 271-276.	2.8	48
80	Molecular cytogenetics characterization of a novel translocation involving chromosomes 17 and 19 in a Ph+ adult acute lymphoblastic leukaemia. British Journal of Haematology, 2002, 119, 488-491.	2.5	1